A Novel Therapeutic Targeting the tPA-NMDAr Interaction for Multiple System Atrophy
Objective: LYS241, a first-in-class, humanized, and optimized monoclonal antibody, designed to inhibit the interaction between tissue plasminogen activator (tPA) and N-methyl-D-aspartate receptor (NMDAr), has demonstrated…Healthcare Resource Utilization and Costs of Multiple System Atrophy in the United States: An Observational Database Study
Objective: To assess the direct healthcare costs and healthcare resource utilization (HCRU) of MSA in the US commercially insured population. Background: MSA is a rare,…MobilityAPP: A randomized-controlled trial evaluating gait-focused physiotherapy in Parkinson’s disease and atypical parkinsonian syndromes
Objective: Effect on gait and balance of gait-focused physiotherapy compared to standard-of-care physiotherapy in patients with MSA, PSP and PD. Background: Physiotherapy is a crucial element…Device-aided Therapies in Multiple System Atrophy: Long-term Follow-up Case Series
Objective: To describe real-world long-term outcomes, tolerability, and complications of device-aided therapies (DAT) in people with multiple system atrophy (MSA; PwMSA) treated at a specialist…Integrated Management of atypical Parkinsonism: A home-based patient-Centered healthcare model using Telenursing. Baseline data from the Multicentre IMPACT study
Objective: To evaluate the effectiveness of a telemedicine-based (‘Telenursing’) home healthcare model, coordinated by a Parkinsonism Nurse Specialist (PKNS), in improving the quality of life…A Randomized, Double-blind Phase 3 Trial of Amlenetug Versus Placebo in Patients with MSA: The MASCOT Trial
Objective: Describe the protocol for a randomized, double-blind phase 3 trial evaluating the efficacy and safety of amlenetug versus placebo in slowing clinical progression in…Incorporating Patient and Care Partner Feedback on the Protocol for a Clinical Trial Assessing Progression in MSA
Objective: Describe the perspectives of people living with MSA (PwMSA) and their care partners on the design and operational characteristics of a phase 3 trial…The IMPACT study: protocol of a randomised controlled single-blind trial evaluating efficacy and cost-effectiveness of telenursing in atypical parkinsonism
Objective: To present the protocol of a study evaluating the efficacy and cost-effectiveness of a 12-month integrated program aimed at improving healthcare delivery and coordinated…Intrathecal Administration of Human Oral Mucosa Neural Crest Stem Cells in Moderate/Advanced Multiple System Atrophy: Report on Ongoing Phase 1 Study
Objective: This first-in-human study aims to evaluate the safety of hOMNSC300 following intrathecal administration in patients with moderate to advanced MSA. Background: Stem cell therapy…ATH434 Slowed Disease Progression in a Phase 2 Study in Multiple System Atrophy
Objective: Evaluate the efficacy and safety of ATH434 treatment in individuals with MSA Background: Multiple system atrophy (MSA) is a rapidly progressive neurodegenerative disorder without…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 10
- Next Page »